LYRA THERAPEUTICS INC's ticker is LYRA and the CUSIP is 55234L105. A total of 44 filers reported holding LYRA THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,525,776 | -3.4% | 1,413,242 | 0.0% | 1.04% | +38.0% |
| Q2 2023 | $5,717,732 | +42.4% | 1,413,242 | -29.2% | 0.76% | +86.5% |
| Q1 2023 | $4,013,914 | -40.7% | 1,996,972 | -7.4% | 0.41% | +16.0% |
| Q4 2022 | $6,773,916 | -46.1% | 2,157,298 | -14.1% | 0.35% | -51.9% |
| Q3 2022 | $12,577,000 | -13.6% | 2,510,302 | -2.6% | 0.73% | -13.8% |
| Q2 2022 | $14,556,000 | +595.5% | 2,576,196 | +394.9% | 0.84% | +1142.6% |
| Q1 2022 | $2,093,000 | -7.2% | 520,544 | +0.6% | 0.07% | -17.1% |
| Q4 2021 | $2,255,000 | -53.7% | 517,244 | -3.0% | 0.08% | -44.6% |
| Q3 2021 | $4,867,000 | +11.7% | 533,417 | -1.7% | 0.15% | +8.8% |
| Q2 2021 | $4,357,000 | +71.9% | 542,644 | +139.4% | 0.14% | +3.8% |
| Q3 2020 | $2,535,000 | +12.9% | 226,703 | +14.5% | 0.13% | -39.4% |
| Q2 2020 | $2,245,000 | – | 198,011 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 2,780,261 | $11,426,873 | 2.01% |
| Nantahala Capital Management | 3,957,542 | $16,265,497 | 1.57% |
| Perceptive Advisors | 12,757,562 | $52,433,579 | 1.52% |
| PURA VIDA INVESTMENTS, LLC | 1,413,242 | $5,717,732 | 0.76% |
| Ikarian Capital, LLC | 978,626 | $4,022,153 | 0.64% |
| VR Adviser, LLC | 924,170 | $3,798,339 | 0.61% |
| Parkman Healthcare Partners LLC | 600,000 | $2,466,000 | 0.43% |
| DAFNA Capital Management LLC | 361,084 | $1,484,055 | 0.41% |
| Soleus Capital Management, L.P. | 592,417 | $2,434,834 | 0.27% |
| ARMISTICE CAPITAL, LLC | 4,012,036 | $16,489,468 | 0.24% |